| OVERALL (N = 1,118) . | Female (N = 624) . | Male (N = 494) . | P-value . | |
|---|---|---|---|---|
| Age | 54.57 ± (13.70) | 55.64 ± (13.70) | 53.22 ± (13.60) | .003* |
| Tumor size | ||||
| Koos I | 157 (14) | 92 (15) | 65 (13) | .488 |
| Koos II | 373 (33) | 201 (32) | 172 (35) | .372 |
| Koos III | 403 (36) | 225 (36) | 178 (36) | 1 |
| Koos IV | 185 (17) | 106 (17) | 79 (16) | .686 |
| Cystic morphology | 59 (5) | 31 (5) | 28 (6) | .687 |
| Shunt-Dependency | 14 (1) | 10 (2) | 4 (1) | .287 |
| Treatment | ||||
| SURGERY | 424 (38) | 222 (36) | 202 (41) | .072 |
| SRS | 694 (62) | 402 (64) | 292 (59) | |
| Incidence of recurrence | ||||
| Overall | 111 (10) | 73 (12) | 38 (8) | .027* |
| SURGERY | 34 (8) | 18 (8) | 16 (8) | .729 |
| SRS | 77 (11) | 55 (14) | 22 (8) | .004* |
| Treatment complications / side effects | 63 (6) | 34 (5) | 29 (6) | .795 |
| CDC | ||||
| 2 | 29 (3) | 14 (2) | 15 (3) | .451 |
| 3a | 31 (3) | 18 (3) | 13 (3) | .856 |
| 3b | 11 (1) | 8 (1) | 3 (1) | .364 |
| > 4 | 0 (0) | 0 (0) | 0 (0) | 1 |
| OVERALL (N = 1,118) . | Female (N = 624) . | Male (N = 494) . | P-value . | |
|---|---|---|---|---|
| Age | 54.57 ± (13.70) | 55.64 ± (13.70) | 53.22 ± (13.60) | .003* |
| Tumor size | ||||
| Koos I | 157 (14) | 92 (15) | 65 (13) | .488 |
| Koos II | 373 (33) | 201 (32) | 172 (35) | .372 |
| Koos III | 403 (36) | 225 (36) | 178 (36) | 1 |
| Koos IV | 185 (17) | 106 (17) | 79 (16) | .686 |
| Cystic morphology | 59 (5) | 31 (5) | 28 (6) | .687 |
| Shunt-Dependency | 14 (1) | 10 (2) | 4 (1) | .287 |
| Treatment | ||||
| SURGERY | 424 (38) | 222 (36) | 202 (41) | .072 |
| SRS | 694 (62) | 402 (64) | 292 (59) | |
| Incidence of recurrence | ||||
| Overall | 111 (10) | 73 (12) | 38 (8) | .027* |
| SURGERY | 34 (8) | 18 (8) | 16 (8) | .729 |
| SRS | 77 (11) | 55 (14) | 22 (8) | .004* |
| Treatment complications / side effects | 63 (6) | 34 (5) | 29 (6) | .795 |
| CDC | ||||
| 2 | 29 (3) | 14 (2) | 15 (3) | .451 |
| 3a | 31 (3) | 18 (3) | 13 (3) | .856 |
| 3b | 11 (1) | 8 (1) | 3 (1) | .364 |
| > 4 | 0 (0) | 0 (0) | 0 (0) | 1 |
Values are presented as the number of patients (%) unless indicated otherwise. Significant P-values (< .05) are highlighted with *.
| OVERALL (N = 1,118) . | Female (N = 624) . | Male (N = 494) . | P-value . | |
|---|---|---|---|---|
| Age | 54.57 ± (13.70) | 55.64 ± (13.70) | 53.22 ± (13.60) | .003* |
| Tumor size | ||||
| Koos I | 157 (14) | 92 (15) | 65 (13) | .488 |
| Koos II | 373 (33) | 201 (32) | 172 (35) | .372 |
| Koos III | 403 (36) | 225 (36) | 178 (36) | 1 |
| Koos IV | 185 (17) | 106 (17) | 79 (16) | .686 |
| Cystic morphology | 59 (5) | 31 (5) | 28 (6) | .687 |
| Shunt-Dependency | 14 (1) | 10 (2) | 4 (1) | .287 |
| Treatment | ||||
| SURGERY | 424 (38) | 222 (36) | 202 (41) | .072 |
| SRS | 694 (62) | 402 (64) | 292 (59) | |
| Incidence of recurrence | ||||
| Overall | 111 (10) | 73 (12) | 38 (8) | .027* |
| SURGERY | 34 (8) | 18 (8) | 16 (8) | .729 |
| SRS | 77 (11) | 55 (14) | 22 (8) | .004* |
| Treatment complications / side effects | 63 (6) | 34 (5) | 29 (6) | .795 |
| CDC | ||||
| 2 | 29 (3) | 14 (2) | 15 (3) | .451 |
| 3a | 31 (3) | 18 (3) | 13 (3) | .856 |
| 3b | 11 (1) | 8 (1) | 3 (1) | .364 |
| > 4 | 0 (0) | 0 (0) | 0 (0) | 1 |
| OVERALL (N = 1,118) . | Female (N = 624) . | Male (N = 494) . | P-value . | |
|---|---|---|---|---|
| Age | 54.57 ± (13.70) | 55.64 ± (13.70) | 53.22 ± (13.60) | .003* |
| Tumor size | ||||
| Koos I | 157 (14) | 92 (15) | 65 (13) | .488 |
| Koos II | 373 (33) | 201 (32) | 172 (35) | .372 |
| Koos III | 403 (36) | 225 (36) | 178 (36) | 1 |
| Koos IV | 185 (17) | 106 (17) | 79 (16) | .686 |
| Cystic morphology | 59 (5) | 31 (5) | 28 (6) | .687 |
| Shunt-Dependency | 14 (1) | 10 (2) | 4 (1) | .287 |
| Treatment | ||||
| SURGERY | 424 (38) | 222 (36) | 202 (41) | .072 |
| SRS | 694 (62) | 402 (64) | 292 (59) | |
| Incidence of recurrence | ||||
| Overall | 111 (10) | 73 (12) | 38 (8) | .027* |
| SURGERY | 34 (8) | 18 (8) | 16 (8) | .729 |
| SRS | 77 (11) | 55 (14) | 22 (8) | .004* |
| Treatment complications / side effects | 63 (6) | 34 (5) | 29 (6) | .795 |
| CDC | ||||
| 2 | 29 (3) | 14 (2) | 15 (3) | .451 |
| 3a | 31 (3) | 18 (3) | 13 (3) | .856 |
| 3b | 11 (1) | 8 (1) | 3 (1) | .364 |
| > 4 | 0 (0) | 0 (0) | 0 (0) | 1 |
Values are presented as the number of patients (%) unless indicated otherwise. Significant P-values (< .05) are highlighted with *.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
